News

Deal Announcements

Tigris Pharma Secures Series C Venture Capital Funding

Friday, October 1, 2010 5:56:00 AM PDT | VentureDeal Staff
Bonita Springs, Florida  --  Cancer pharmaceutical company Tigris Pharmaceuticals has garnered $6.5 million in its third round of venture capital financing.

Tigris is developing a topical treatment for pre-cancerous and cancerous lesions associated with HPV.

Wexford Spectrum Investors, Sonostar Capital Partners and others invested in the round. The company said it would use the funding proceeds to advance its clinical product pipeline.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1